Chemotherapy for recurrent malignant glioma with combined usage of temozolomide and GSK3beta-inhibiting drugs

Chemotherapy for recurrent malignant glioma with combined usage of temozolomide and GSK3beta-inhibiting drugs - GSK3beta inhibitor for recurrent malignant glioma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005111

Enrollment

Registered

2011-02-21

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent glioblastoma

Interventions

GSK cocktail is daily administered from the detection of recurrence until unavailable state.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) age: 15<, 90> 2)Treatment-failure glioblastoma multiforme patients who have been histologically diagnosed as glioblastoma multiforme. 3)No allergy to the drugs administered. 4) Sufficient function of vital organs including heart, lung, liver, kidney and bone marrow. 5) No obstacles on drug administration. 6) Written informed consents are obtained from patients after giving sufficient explanations and obtaining their understandings about disease conditions.

Exclusion criteria

Exclusion criteria: 1) Allergy to the drugs administered. 2) Patients who are pregnant and/or breast feeding. 3) Any patients disqualified by a study physician because of medical, psychological, or any other factors.

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Efficacy: response on MRI and progression-free survival	—

Countries

Japan

Contacts

Public ContactMitsutoshi Nakada

Kanazawa University Department of Neurosurgery

076-265-2384

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026